Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis
Alessandro Rizzo(Istituto Tumori Bari), Mario Giuliano(Regione Campania), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Filippo Montemurro(Roche (Switzerland)), Grazia Arpino(University of Naples Federico II), Francesca Matilde Schipilliti(Azienda Ospedaliera Sant'Andrea), Lucia Del Mastro(Ospedale Policlinico San Martino), Fabio Puglisi(University of Udine), Silvana Acquafredda(Istituto Tumori Bari), Francesco Di Costanzo
Cited by 31
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830